prognost factor unselect patient nonseminomat metastat testicular cancer multicent experi between consecut patient metastat nonseminomat testicular cancer swedish norwegian testicular cancer swenoteca project hospit treatment plan chemotherapi cycl cisplatin vinblastin bleomycin surgic resect residu tumor mass median observ time month overal surviv rate univari analysi paramet prognosi extent diseas medic research council mrc prechemotherapi level serum alpha-fetoprotein afp human chorion gonadotropin hcg lactat dehydrogenas ldh patient age presenc extrapulmonari hematogen metastas larg lymph node metastas patient week orchiectomi start chemotherapi interv place treatment larg oncolog unit unit signific prognost factor patient large-volum LV very-large-volum vlv diseas multivari analysi cox regress proport hazard model assess patient follow advers prognost factor high-volum metastat burden age year prechemotherapi afp micrograms/l and/or hcg u/l interv orchiectomi start chemotherapi week place treatment final outcom patient LV vlv diseas presenc follow risk factor addit prognost factor afp micrograms/l hcg u/l liver metastas brain metastas bone metastas retroperiton tumor equal cm mediastin tumor equal cm 